1. Pinheiro PS, Jones PD, Medina H, et al. Incidence of etiology-specific hepatocellular carcinoma: diIverging trends and significant heterogeneity by race and ethnicity. Clin Gastroenterol Hepatol. Published online September 6, 2023. doi:10.1016/j.cgh.2023.08.016

2. Ju MR, Karalis JD, Chansard M, et al. Variation of hepatocellular carcinoma treatment patterns and survival across geographic regions in a veteran population. Ann Surg Oncol. 2022;29(13):8413-8420. doi:10.1245/s10434-022-12390-7

3. Veterans Health Administration. VA collaborative consensus on a pathway for the development of a multidisciplinary team to manage hepatocellular carcinoma. VA Liver Cancer Summit; March 8, 2019; Miami, FL. Accessed December 14, 2023. https://www.hepatitis.va.gov/pdf/HCC-multidisciplinary-management-best-practices.pdf

4. Emerson L. Hepatocellular carcinoma treatment, survival varies among VA regions. US Medicine. Published June 12, 2023. Accessed December 14, 2023. https://www.usmedicine.com/clinical-topics/cancer/hepatocellular-carcinoma/hepatocellular-carcinoma-treatment-survival-varies-among-va-regions/

5. Agarwal PD, Haftoglou BA, Ziemlewicz TJ, Lucey MR, Said A. Psychosocial barriers and their impact on hepatocellular carcinoma care in US veterans: tumor board model of care. Fed Pract. 2022;39(suppl 2):S32-S36. doi:10.12788/fp.0272

6. Ito T, Nguyen MH. Perspectives on the underlying etiology of HCC and its effects on treatment outcomes. J Hepatocell Carcinoma. 2023;10:413-428. doi:10.2147/JHC.S347959

7. Garren P, Serper M. Chronic hepatitis B in US veterans. Curr Hepatol Rep. 2019;18(3):310-315. doi:10.1007/s11901-019-00479-9

8. US Department of Veteran Affairs. Hepatitis C: information for veterans. Published November 2022. Accessed December 14, 2023. https://www.hepatitis.va.gov/pdf/Hepatitis-C-Factsheet-Veterans.pdf

9. Janevska D, Chaloska-Ivanova V, Janevski V. Hepatocellular carcinoma: risk factors, diagnosis and treatment. Open Access Maced J Med Sci. 2015;3(4):732-736. doi:10.3889/oamjms.2015.111

10. Elderkin J, Al Hallak N, Azmi AS, et al. Hepatocellular carcinoma: surveillance, diagnosis, evaluation and management. Cancers (Basel). 2023;15(21):5118. doi:http://doi.org/10.3390/cancers15215118

11. Wei H, Yang J, Lu R, et al. m⁶A modification of AC026356.1 facilitates hepatocellular carcinoma progression by regulating the IGF2BP1-IL11 axis. Sci Rep. 2023;13(1):19124. doi:10.1038/s41598-023-45449-w

12. Espinoza M, Muquith M, Lim M, Zhu H, Singal AG, Hsiehchen D. Disease etiology and outcomes after atezolizumab plus bevacizumab in hepatocellular carcinoma: post-hoc analysis of IMbrave150. Gastroenterology. 2023;165(1):286-288.e4. doi:10.1053/j.gastro.2023.02.042

13. Zhang H, Zhang W, Jiang L, Chen Y. Recent advances in systemic therapy for hepatocellular carcinoma. Biomark Res. 2022;10(1):3. doi:10.1186/s40364-021-00350-4

14. Johnson P, Zhou Q, Dao DY, Lo YMD. Circulating biomarkers in the diagnosis and management of hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol. 2022;19(10):670-681. doi:10.1038/s41575-022-00620-y

15. US Department of Veteran Affairs. VA Cooperative Studies Program (CSP). CSP #2023 PREventing liver cancer Mortality through Imaging with Ultrasound vs MRI (PREMIUM STUDY). Updated July 2022. Accessed December 14, 2023. https://www.vacsp.research.va.gov /CSP_2023/CSP_2023.asp

Cancer Data Trends 2024: Hepatocellular Carcinoma